A phase I trial of NKI 1339 in combination with other antineoplastics for the treatment of various cancers, including liver, gastric, pancreatic and non-small cell lung cancers.
Phase of Trial: Phase I
Latest Information Update: 17 Nov 2011
At a glance
- Drugs IT 139 (Primary) ; Antineoplastics
- Indications Cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer; Pancreatic cancer
- Focus Therapeutic Use
- 17 Nov 2011 New trial record